세계의 경피 약물 전달 시스템 시장(2023-2030년)

Title: Global Transdermal Drug Delivery Systems Market Size, Share & Trends Analysis Report by Type (Patches and gel), by Application (Hypertension, Motion Sickness, Pain Management and Others),Forecast Period (2023-2030).

The global transdermal drug delivery systems market is anticipated to grow at a CAGR of 6.5% during the forecast period (2023-2030). Transdermal drug delivery system (TDDS) is the systems categorized under the controlled drug delivery, where drugs are delivered through the skin at a fixed and controlled rate. These systems are used for treating various disease conditions such as cardiovascular disorders, and central nervous system disorders, etc. Recently in April 2023, FDA updated the documents to clarify the appropriate methods sponsors should consider while measuring the surface area of the TDS product that is expected to adhere to a patient's skin and how to statistically analyze that data. That why FDA updates generic transdermal and topical delivery systems guidance's. It issued two revised draft guidance for generic drug submissions that use transdermal and topical delivery systems (TDS). The revised guidance make numerous technical clarifications that abbreviated new drug application (ANDA) sponsors should consider when filing their premarket application.

Segmental Outlook

The global transdermal drug delivery systems market is segmented on the type and application. Based on the type, the market is sub-segmented into patches and gel. Based on the application, the market is sub-segmented into hypertension, motion sickness, pain management and others. Among the type, the patches sub-segment is anticipated to hold a considerable share of the market. Owing to its use in pain management, which is boosting the market growth. And the increasing cases of cancer, lead accelerated embracing of pain patches.

The Pain Management Sub-Segment is Anticipated to Hold a Considerable Share of the Global Transdermal Drug Delivery Systems Market

Among the application, the Pain management sub-segment is expected to hold a considerable share of the global transdermal drug delivery system market. The rising patient preference for pain-free drug administration has led to a significant surge in the adoption rate of adhesive skin patches that administer drugs, which is anticipated to present the market with high growth potential. Hence Companies are focusing to enter and improve in this segment. For an instance, in June 2023, Innocan Pharma Corporation has announced the filing of its most recent patent application to the United States Patent and Trademark Office (USPTO). This move is in line with the Company's ongoing strategy to expand the breadth of its distinctive combined Cannabis and Magnesium topical pain-relief technology.

Regional Outlook

The global transdermal drug delivery systems market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Europe is anticipated to hold a prominent share of the market across the globe, owing to presence of advanced healthcare infrastructure facilities in countries like Germany, UK and Russia.

The North America Region is Expected to Grow at a Significant CAGR in the Global Transdermal Drug Delivery Systems Market

Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the region is driven by the rising prevalence of targeted diseases (such as chronic pain, central nervous system disorders, and cardiovascular diseases) in the region, and the increasing number of research activities related to transdermal drug delivery systems. Hence, there is considerable shift of the country towards the adoption of the Transdermal Drug Delivery Systems market solutions. For an instance in April 2023, DifGen Pharmaceuticals LLC announced that it has acquired Aveva Drug Delivery Services Inc. a fully integrated developer and manufacturer of Transdermal Delivery Systems (TDS) and Oral Dissolvable Films (ODF). This strategic investment allows us to expand our R&D & manufacturing capabilities in offering complex dosage forms and secure supply to our valuable partners with local US based manufacturing. Most importantly, it will provide patients affordable lifesaving medication with highest quality and consistent supply".

Market Players Outlook

The major companies serving the transdermal drug delivery systems market includes Boehringer Ingelheim GmbH, Echo Therapeutics Inc., GlaxoSmithKline plc, Hisamitsu Pharmaceutical Co. Inc., Mylan Pharmaceuticals, Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in June 2023, Kyung Hee signed a new technology transfer agreement with Dasan Pharmaceutical for a pioneering transdermal drug delivery material technology that incorporates a novel polymer compound developed by Professor Dokyoung Kim of the College of Medicine.

The Report Covers:

• Market value data analysis of 2022 and forecast to 2030.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global transdermal drug delivery systems market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Region

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Findings
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
• 3.2. 3M Company
  • 3.2.1. Overview
  • 3.2.2. Financial Analysis
  • 3.2.3. SWOT Analysis
  • 3.2.4. Recent Developments
• 3.3. Johnson & Johnson
  • 3.3.1. Overview
  • 3.3.2. Financial Analysis
  • 3.3.3. SWOT Analysis
  • 3.3.4. Recent Developments
• 3.4. Skyepharma Production SAS
  • 3.4.1. Overview
  • 3.4.2. Financial Analysis
  • 3.4.3. SWOT Analysis
  • 3.4.4. Recent Developments
• 3.5. Key Strategy Analysis

4. Market Segmentation

• 4.1. Global Transdermal Drug Delivery Systems Market by Type
  • 4.1.1. Patches
  • 4.1.2. Gel
• 4.2. Global Transdermal Drug Delivery Systems Market by Application
  • 4.2.1. Hypertension
  • 4.2.2. Motion Sickness
  • 4.2.3. Pain Management
  • 4.2.4. Others (+Infection, Hormone, Respiratory and Metabolic)

5. Regional Analysis

• 5.1. North America
  • 5.1.1. United States
  • 5.1.2. Canada
• 5.2. Europe
  • 5.2.1. UK
  • 5.2.2. Germany
  • 5.2.3. Italy
  • 5.2.4. Spain
  • 5.2.5. France
  • 5.2.6. Rest of Europe
• 5.3. Asia-Pacific
  • 5.3.1. China
  • 5.3.2. India
  • 5.3.3. Japan
  • 5.3.4. South Korea
  • 5.3.5. Rest of Asia-Pacific
• 5.4. Rest of the World

6. Company Profiles

• 6.1. 4P Therapeutics, LLC
• 6.2. Altaris
• 6.3. Bayer AG
• 6.4. Biogel Technology, Inc.
• 6.5. Boehringer Ingelheim GmbH
• 6.6. Echo Therapeutics, Inc.
• 6.7. GlaxoSmithKline plc
• 6.8. Hisamitsu Pharmaceutical Co. Inc.
• 6.9. Mylan Pharmaceuticals, Inc.
• 6.10. Novartis AG
• 6.11. Noven Pharmaceuticals, Inc.
• 6.12. Purdue Pharma L.P.
• 6.13. Transdermal Technologies, Inc.
• 6.14. Viatris Inc.
• 6.15. Watson Pharmaceuticals, Inc.